Skip to content
DataLookout
Menu

NCT07389174

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

StatusNot Yet Recruiting
PhaseEarly Phase 1
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 2027 to Dec 2027 Show 4 more changesShow less
    • Start date: Feb 2026 to Jun 2027
    • Eligibility criteria expanded, about 7 words
    • Study completion pushed from Jun 2027 to Dec 2028
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Adverse Events (AEs)
Timeframe: From baseline to primary completion, which may take up to 24 to 48 weeks

Secondary (5)

PSA Undetectable Rate
PSA Response Rate
Time to CRPC(Castration-Resistant Prostate Cancer)
Disease Control Rate (DCR)
Radiographic Progression-Free Survival (rPFS )

Arms and interventions

High-Volume mHSPC: Standard of CareActive comparator

Participants with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). Participants in this arm receive standard-of-care endocrine therapy alone.

High-Volume mHSPC: LC-K76 + Standard Endocrine TherapyExperimental

Participants with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). High volume is defined as the presence of visceral metastases or ≥ 4 bone lesions with ≥ 1 beyond the vertebral bodies and pelvis. Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.

Low-Volume mHSPC: LC-K76 + Standard Endocrine TherapyExperimental

Participants with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). Low volume is defined as ≤ 3 bone metastases confined to the vertebral bodies and pelvis, and no visceral metastases. Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.

Low-Volume mHSPC: Standard of CareActive comparator

Participants with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). Participants in this arm receive standard-of-care endocrine therapy alone.

Drugs: Standard Endocrine Therapy

Dietary supplements: LC-K76

Sites

1 site in 1 country

  • Changzheng hospitalShanghai, Shanghai Municipality, China